Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has filed a prospectus with the SEC under Rule 424(b)(3) for the resale of up to 2,486,270,400 ordinary shares, represented by 6,215,676 American Depositary Shares (ADSs), by selling shareholders. These shares include those issuable upon the exercise of warrants from a private placement in May 2024. The selling shareholders are identified in the prospectus, with the sale potentially involving ordinary shares obtained through warrant exercises. The company will not receive proceeds from the sale of the ADSs by the selling shareholders but may receive proceeds from any exercised warrants. The ADSs are listed on the NASDAQ Capital Market under the symbol 'BDRX.' The prospectus also outlines the risks involved in investing, tax considerations, and legal matters, including the company's jurisdiction in the UK, which may affect the enforcement of civil liabilities. The date of the prospectus is June 14, 2024.

Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has filed a prospectus with the SEC under Rule 424(b)(3) for the resale of up to 2,486,270,400 ordinary shares, represented by 6,215,676 American Depositary Shares (ADSs), by selling shareholders. These shares include those issuable upon the exercise of warrants from a private placement in May 2024. The selling shareholders are identified in the prospectus, with the sale potentially involving ordinary shares obtained through warrant exercises. The company will not receive proceeds from the sale of the ADSs by the selling shareholders but may receive proceeds from any exercised warrants. The ADSs are listed on the NASDAQ Capital Market under the symbol 'BDRX.' The prospectus also outlines the risks involved in investing, tax considerations, and legal matters, including the company's jurisdiction in the UK, which may affect the enforcement of civil liabilities. The date of the prospectus is June 14, 2024.